Lars Rydén

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year

Klas Malmberg, Lars Rydén, Suad Efendić et al. · Journal of the American College of Cardiology · 1995 · 1.6K citations

Medicine, Cardiology, Internal Medicine +11

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

K. Malmberg, Lars Rydén, Hans Wedel et al. · European Heart Journal · 2005 · 1.1K citations · Full text

Medicine, Cardiology, Internal Medicine +16

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries

Kornelia Kotseva, David Wood, Dirk De Bacquer et al. · European Journal of Preventive Cardiology · 2015 · 1K citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society

Valentı́n Fuster, Lars Rydén, D.S. Cannom et al. · EP Europace · 2006 · 668 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17